Tagged with BIO

Samsung Korea’s economy has been dominated for decades by chaebols, large family-owned business conglomerates like Samsung, Hyundai, and LG, known for their hierarchical structures and success in Korea’s traditional sectors. However, a number of these big businesses are today making investments in the life sciences area – and those that started…

biotech Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their second generation botulinum toxin product that will be commercialized globally (outside of Japan and Korea) by Botox manufacturer Allergan. What…

infrastructure Dogan Taşkent, president of the Swiss Chamber of Commerce in Turkey discusses the most successful models for innovation in Turkey, the current status of start-up incubators in the country, and how Turkey can learn from the Swiss model for innovation. What are the main economic challenges that Turkey is facing…

R&D Pfizer Turkey has taken a strong supporting role in Turkey’s current strategic development plan by localizing the production of their Prix Galien winning Prevnar vaccine. Country Manager Elif Aral discusses this facility’s role as a role model in the industry, and how the country can improve investment incentives to better…

biosimilars Akhilesh Vijay came to Accord Healthcare Peru following a career at Intas Pharmaceutical in India. He urges the implementation of regulation for Biosimilars and discusses his strategy for future growth as a leading Indian generic affiliate. How did you integrate yourself here, and what was the initial strategy? What is…

Genzyme Genzyme Turkey’s general manager discusses diagnosis and treatment access issues for rare diseases, the need for prioritization of patient welfare in all aspects of health policy, and the importance of the Turkish market and its potential to Genzyme globally. For rare diseases, do Turkish patients have adequate access to the…

biotech Landsteiner is betting on biotech and genomics. The head of new developments and the head of genomic research share their views on the future of the company as well as the importance of embedding new technology in new product developments to better adapt to the changing needs of the Mexican…

Amgen One of the new generation of pharmaceutical general managers in Romania discusses the complexities of introducing innovative therapies on the market and explains how the country has become the ‘to-go-to’ destination for relocating pharma companies’ support services. Amgen has been present in Romania as far back as 2004. Can you…

biotech As in human health, innovation is key in the animal health industry. The CEO and second generation at the head of Tornel presents the company’s most important milestones since its establishment back in 1976, how the Group started export operations to the Middle East as well as how it is collaborating…

basic research Considered one of the leading medical authorities in the country, David Kershenobich provides an overview about the new challenges faced by the Mexican healthcare system with the transition from infectious to chronic-degenerative diseases, how the institute is implementing new patient centered care models to encourage prevention of risk factors and…

biotech SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a cure for cancer’.   Could you please introduce yourself Dr. Moon, and tell us how you became involved with SillaJen? …

biosimilars Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the opportunities in Biosimilar markets as well as the potential impact the Samsung brand will bring to the pharmaceutical industry. As…